Biological aggressiveness evaluation in prostate carcinomas: Immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3+3) adenocarcinomas

European Journal of Histochemistry

Volumn 47, Issue 2, 2003, Pages 129-132

  Cappello, Francesco ^a,c   Palma, A ^a   Martorana, A ^a   Rappa, F ^a   Cabibi, D ^a   Barresi, E ^a   Melloni, D ^b   Farina, F ^a   Aragona, F ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c NONE   (Italy)

Author keywords

Proliferative index; Prostate cancerogenesis; Tumoral differentiation; Tumoral prognosis

Indexed keywords

BIOLOGICAL MARKER; CYCLINE; MUTANT PROTEIN; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROTEIN ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; VALIDATION PROCESS;

EID: 0038587749     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/817     Document Type: Article

References (16)

1. Boring CC, Squires TS, Tong T. Cancer Statistic, 1992. Cancer J Clin 1992;42:19-38.
2. Bruner JM, Connelly JH, Saya H. p53 protein immunostaining in routinely processed paraffin-embedded sections. Mod Pathol 1993;6: 189-94.
3. Cappello F, Barnes L. Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis. Pathology 2001;33:142-8.
4. Cappello B, Bellafiore M, Palma A, Bucchieri F. Defective apoptosis and tumorigenesis. Role of p53 mutation and Fas-FasL system dysregulation. Eur J Histochem 2002;46:199-208.
5. Fox SB, Persad RA, Royds J, Kone RN, Silcocks PB, Colins CC. p53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinant? J Urol 1993;150:490-4.
6. Gleason DF. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, Ed. Urologic pathology: the prostate. Philadelphia: Lea & Febiger; 1977. p. 171-97.
7. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, et al. Proliferation cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-94.
8. Kallakury BVS, Figge J, Ross JS, Fisher HA, Figge HL, Jenninngs TA. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 1994;25:92-7.
9. Kramer SA, Spahr J, Brendler CB, Glenn JF, Paulson DF. Experience with Gleason's histopathologic grading in prostatic cancer. J Urol 1980;124:223-30.
10. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
11. Montironi R, Galuzzi CM, Diamanti L, Giannulis I, Pisani E, Scarpelli M. Proliferating cell nuclear antigen (PCNA) in prostatic invasive adenocarcinoma. Is the proliferation state in the marginal zone of the tumor higher than in the central part? Anticancer Res 1993;13:129-32.
12. Oren M. p53: the ultimate tumor suppressor gene? FASEB J 1992; 6:3169-76.
13. Papadopoulos I, Rudolph P, Wirth B, Weichert-Jacobsen K. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology 1996;48:261-8.
14. Samaan S, Butler J, Morale B. p53 overaccumulation correlates with high tumor grade in prostatic adenocarcinoma. Am J Clin Pathol 1993;99:336.
15. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106-9.
16. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol 1992; 23:273-9.